Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | CCNK | O75909 | 2/20 | 0.51 |
| ▸ | DDB1 | Q16531 | 2/20 | 0.51 |
| ▸ | CDK12 | Q9NYV4 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | AOC3 | Q16853 | 5/20 | 0.48 |
| ▸ | MAOB | P27338 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | PDE5A | O76074 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | CASP3 | P42574 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.44 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.44 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24101425 | 0.86 | CCNK (0.66) | SMN1; SMN2KMT2ACCNKDDB1CDK12 | |
| SCHEMBL5484301 | 0.83 | CDK2 (0.57) | SMN1; SMN2KMT2ACCNKDDB1CDK12 | |
| SCHEMBL5484375 | 0.82 | CCNE1 (0.51) | SMN1; SMN2KMT2ACCNKDDB1CDK12 | |
| SCHEMBL5488695 | 0.81 | KMT2A (0.57) | SMN1; SMN2KMT2ACCNKDDB1CDK12 | |
| SCHEMBL5482981 | 0.81 | CCNK (0.48) | SMN1; SMN2KMT2ACCNKDDB1CDK12 | |
| SCHEMBL13158536 | 0.80 | CCNE1 (0.48) | SMN1; SMN2KMT2AMEN1AOC3LMNA | |
| SCHEMBL5487537 | 0.79 | CCNK (0.46) | SMN1; SMN2KMT2ACCNKDDB1CDK12 | |
| SCHEMBL6366716 | 0.79 | CCNK (0.46) | SMN1; SMN2KMT2ACCNKDDB1CDK12 | |
| SCHEMBL6365990 | 0.77 | CCNK (0.45) | SMN1; SMN2KMT2ACCNKDDB1CDK12 | |
| SCHEMBL5482486 | 0.77 | CCNK (0.44) | SMN1; SMN2KMT2ACCNKDDB1CDK12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1204649-B1 | ARYLMETHYL-CARBONYLAMINO-THIAZOLE DERIVATIVES AND THEIR USE AS ANTITUMOR AGENTS | PFIZER ITALIA SRL (IT) | 2007-10-17 | — | — | EP | disclosed |
| US-20050004120-A1 | Arylmethyl-carbonylamino-thiazole derivatives and their use as antitumor agents | PHARMACIA ITALIS S.P.A. (IT) | 2005-01-06 | — | — | US | disclosed |
| US-6784198-B1 | 2-(ARYLMETHYL-CARBONYLAMINO)-1,3-THIAZOLE DERIVATIVES; CDK/CYCLIN KINASE INHIBITORY ACTIVITY | PHARMACIA ITALIA S.P.A. (IT) | 2004-08-31 | — | — | US | disclosed |
| EP-1204649-A1 | ARYLMETHYL-CARBONYLAMINO-THIAZOLE DERIVATIVES AND THEIR USE AS ANTITUMOR AGENTS | Pharmacia Italia S.p.A. (IT) | 2002-05-15 | — | — | EP | disclosed |
| WO-2001014353-A1 | ARYLMETHYL-CARBONYLAMINO-THIAZOLE DERIVATIVES AND THEIR USE AS ANTITUMOR AGENTS | PHARMACIA ITALIA, S.P.A. (IT) | 2001-03-01 | — | — | WO | disclosed |
| US-6114365-A | Arylmethyl-carbonylamino-thiazole derivatives, process for their preparation, and their use as antitumor agents | PHARMACIA & UPJOHN S.P.A. (IT) | 2000-09-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050004120-A1 | Arylmethyl-carbonylamino-thiazole derivatives and their use as antitumor agents | CCAR2, BCL2, ROS1 | SMN1; SMN2 1806/4885KMT2A 1612/4885CCNK 214/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.